Royal Bank of Canada’s Galectin Therapeutics GALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8K | Buy |
1,632
+565
| +53% | +$1.46K | ﹤0.01% | 6769 |
|
|
2026
Q1 | $3K | Sell |
1,067
-5,108
| -83% | -$15.5K | ﹤0.01% | 6586 |
|
|
2025
Q4 | $25K | Buy |
6,175
+5,699
| +1,197% | +$30K | ﹤0.01% | 5913 |
|
|
2025
Q3 | $2K | Sell |
476
-24,457
| -98% | -$92K | ﹤0.01% | 6880 |
|
|
2025
Q2 | $52K | Buy |
24,933
+24,389
| +4,483% | +$36.5K | ﹤0.01% | 5900 |
|
|
2025
Q1 | $0 | Sell |
544
-1,299
| -70% | -$1.82K | ﹤0.01% | 6960 |
|
|
2024
Q4 | $3K | Sell |
1,843
-1,738
| -49% | -$4.17K | ﹤0.01% | 6643 |
|
|
2024
Q3 | $10K | Buy |
3,581
+45
| +1% | +$111 | ﹤0.01% | 6328 |
|
|
2024
Q2 | $7K | Buy |
+3,536
| New | +$10.7K | ﹤0.01% | 6446 |
|
|
2024
Q1 | – | Sell |
-1,069
| Closed | -$2K | – | 7208 |
|
|
2023
Q4 | $2K | Buy |
+1,069
| New | +$2.07K | ﹤0.01% | 6802 |
|
|
2023
Q3 | – | Sell |
-324
| Closed | – | – | 7246 |
|
|
2023
Q2 | $0 | Buy |
324
+295
| +1,017% | +$500 | ﹤0.01% | 7390 |
|
|
2023
Q1 | $0 | Buy |
+29
| New | +$47 | ﹤0.01% | 7192 |
|
|
2022
Q4 | – | Sell |
-296
| Closed | – | – | 7393 |
|
|
2022
Q3 | $0 | Buy |
+296
| New | +$553 | ﹤0.01% | 7583 |
|
|
2021
Q4 | – | Sell |
-2,500
| Closed | -$10K | – | 7741 |
|
|
2021
Q3 | $10K | Sell |
2,500
-2,897
| -54% | -$9.82K | ﹤0.01% | 6955 |
|
|
2021
Q2 | $18K | Buy |
5,397
+2,033
| +60% | +$7.24K | ﹤0.01% | 6618 |
|
|
2021
Q1 | $7K | Sell |
3,364
-216
| -6% | -$484 | ﹤0.01% | 6936 |
|
|
2020
Q4 | $8K | Buy |
3,580
+2,728
| +320% | +$7.16K | ﹤0.01% | 6477 |
|
|
2020
Q3 | $2K | Sell |
852
-334
| -28% | -$935 | ﹤0.01% | 6313 |
|
|
2020
Q2 | $4K | Sell |
1,186
-10,826
| -90% | -$27.2K | ﹤0.01% | 6097 |
|
|
2020
Q1 | $24K | Buy |
12,012
+10,768
| +866% | +$26.2K | ﹤0.01% | 5461 |
|
|
2019
Q4 | $3K | Sell |
1,244
-166
| -12% | -$577 | ﹤0.01% | 6482 |
|
|
2019
Q3 | $5K | Buy |
1,410
+310
| +28% | +$1.12K | ﹤0.01% | 6025 |
|
|
2019
Q2 | $5K | Hold |
1,100
| – | – | ﹤0.01% | 6298 |
|
|
2019
Q1 | $6K | Hold |
1,100
| – | – | ﹤0.01% | 6192 |
|
|
2018
Q4 | $4K | Sell |
1,100
-1,825
| -62% | -$8.72K | ﹤0.01% | 6222 |
|
|
2018
Q3 | $18K | Buy |
2,925
+1,325
| +83% | +$7.29K | ﹤0.01% | 5737 |
|
|
2018
Q2 | $10K | Buy |
1,600
+1,000
| +167% | +$4.87K | ﹤0.01% | 5817 |
|
|
2018
Q1 | $3K | Sell |
600
-92
| -13% | -$429 | ﹤0.01% | 6047 |
|
|
2017
Q4 | $2K | Buy |
692
+666
| +2,562% | +$1.68K | ﹤0.01% | 6270 |
|
|
2017
Q3 | $0 | Buy |
26
+23
| +767% | +$46 | ﹤0.01% | 6788 |
|
|
2017
Q2 | $0 | Buy |
+3
| New | +$8 | ﹤0.01% | 6625 |
|
|
2017
Q1 | – | Sell |
-167
| Closed | – | – | 6669 |
|
|
2016
Q4 | $0 | Buy |
+167
| New | +$148 | ﹤0.01% | 6681 |
|
|
2016
Q3 | – | Sell |
-48
| Closed | – | – | 6451 |
|
|
2016
Q2 | $0 | Buy |
+48
| New | +$70 | ﹤0.01% | 6417 |
|
|
2016
Q1 | – | Sell |
-255
| Closed | – | – | 6457 |
|
|
2015
Q4 | $0 | Sell |
255
-167
| -40% | -$383 | ﹤0.01% | 6706 |
|
|
2015
Q3 | $0 | Buy |
422
+155
| +58% | +$366 | ﹤0.01% | 6685 |
|
|
2015
Q2 | $0 | Buy |
267
+167
| +167% | +$503 | ﹤0.01% | 6631 |
|
|
2015
Q1 | $0 | Hold |
100
| – | – | ﹤0.01% | 6230 |
|
|
2014
Q4 | $0 | Hold |
100
| – | – | ﹤0.01% | 6208 |
|
|
2014
Q3 | $1K | Hold |
100
| – | – | ﹤0.01% | 5861 |
|
|
2014
Q2 | $1K | Hold |
100
| – | – | ﹤0.01% | 5807 |
|
|
2014
Q1 | $2K | Sell |
100
-12
| -11% | -$171 | ﹤0.01% | 5732 |
|
|
2013
Q4 | $1K | Buy |
112
+12
| +12% | +$111 | ﹤0.01% | 5826 |
|
|
2013
Q3 | $1K | Sell |
100
-150
| -60% | -$1.01K | ﹤0.01% | 5957 |
|
|
2013
Q2 | $1K | Buy |
+250
| New | +$1.02K | ﹤0.01% | 5713 |
|
Other funds holding GALT
WANY
Royal Bank of Canada's GALT Position: Q2 2026 in Review
Royal Bank of Canada increased its Galectin Therapeutics (GALT) stake by 53% in Q2 2026, buying an estimated $1.46K and bringing the position to 1,632 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #6769.
Royal Bank of Canada first reported a position in GALT in Q2 2013 and has held it in 44 quarters since. The position peaked at $52K in Q2 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.
- Royal Bank of Canada held 1,632 shares of Galectin Therapeutics worth $8K as of Q2 2026.
- Royal Bank of Canada bought 565 Galectin Therapeutics shares in Q2 2026, an estimated $1.46K.
- Galectin Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #6769 holding.
- Royal Bank of Canada first reported a position in Galectin Therapeutics in Q2 2013 and has held it in 44 quarters since.
- Royal Bank of Canada's Galectin Therapeutics position peaked at $52K in Q2 2025.
- 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.
Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.